Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study
Introduction Myasthenia gravis (MG), an IgG-mediated autoimmune disorder targeting neuromuscular junctions, shows refractory in 12–20% of generalised MG (gMG) patients despite immunotherapies. Plasma exchange (PLEX) transiently depletes pathogenic mediators, while neonatal Fc receptor antagonists (e...
Saved in:
| Main Authors: | Lu Zhang, Kan Wang, Yong Hao, Yangtai Guan, Jing Peng, Li Gao, Song Gao, Qiuju Li, Chong Xie, Yuhui Wang, Yanan Wu, Mengze Zhang, Xiaokun Wang, Chunran Xue, Yiwei Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-08-01
|
| Series: | BMJ Neurology Open |
| Online Access: | https://neurologyopen.bmj.com/content/7/2/e001180.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Similar Items
-
The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis
by: Jia-Jun Cheng, et al.
Published: (2025-08-01) -
Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis
by: Zhouao Zhang, et al.
Published: (2025-04-01) -
Efgartigimod therapy for immune checkpoint inhibitor–associated myasthenia gravis with myositis: a case report
by: Feiteng Qi, et al.
Published: (2025-07-01) -
Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series
by: Zhang Y, et al.
Published: (2025-04-01) -
Case Report: A myasthenia gravis patient complicated with renal failure was effectively treated with efgartigimod
by: Jia Ke, et al.
Published: (2025-03-01)